Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cyclophosphamide × Head & Neck × Clear all

Phase

Phase 1 19 Phase 2 9 Phase 1/2 8 Phase EARLY_PHASE1 3 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 23 Other hematologic neoplasm 18 Breast 10 Myeloid 5 Plasma cell 4 Classical hematology 3 Other neoplasm 2 Dermatologic 2 Thoracic 1 Sarcoma 1 Head & Neck 1

Conditions

Mouth Neoplasms 1

Interventions

Cisplatin 15 Radiotherapy 7 pembrolizumab 6 Radiotherapy, Intensity-Modulated 6 Fluorouracil 6 Docetaxel 6 Magnetic Resonance Spectroscopy 5 Gemcitabine 5 Platinum 4 Paclitaxel 4 1,2-diaminocyclohexaneplatinum II citrate 4 Radiation 3 Cetuximab 3 Carboplatin 3 (225)Ac-DOTA-c(RGDyK) 3 atezolizumab 2 Specimen Handling 2 Iodine-123 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 trametinib 1 toripalimab 1 ponatinib 1 fosbretabulin 1 fluorocholine 1 durvalumab 1 dehydroftorafur 1 dabrafenib 1 combretastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00934739 2015-02-25

A Study of High-Risk Oral Cavity Cancer

National Health Research Institutes, Taiwan

Phase 2/3 Terminated

Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡